Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration

Structural and Functional Criteria of Neuroprotection Effectiveness after Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration

Purpose. Estimate of clinical efficacy of combined use of aflibercept and meldonium at tachyphylaxis of neovascular age-related macular degeneration (nAMD) to ranibizumab. Patients and methods. Comparative analysis of treatment results of nAMD in 25 eyes (25 patients) aged from 52 to 79 years was ca...

Full description

Bibliographic Details
Main Authors:	N. S. Zhajvoronok, V. V. Egorov, G. P. Smoliakova, L. P. Danilova, L. P. Emanova, D. A. Povalyaeva
Format:	Article
Language:	Russian
Published:	Ophthalmology Publishing Group 2019-12-01
Series:	Oftalʹmologiâ
Subjects:	neovascular age-related macular degeneration tachyphylaxis aflibercept meldonium
Online Access:	https://www.ophthalmojournal.com/opht/article/view/1085

Similar Items

Comparison of the effectiveness of various protocols for the transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular AMD
by: A. N. Kulikov, et al.
Published: (2018-11-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

Anti-VEGF therapy of neovascular age-related macular degeneration: from randomized trials to routine clinical practice
by: R. R. Fayzrakhmanov
Published: (2019-06-01)

Aflibercept Treatment Results and Association with Baseline Characteristics in Cases of Newly Diagnosed Neovascular Age-Related Macular Degeneration
by: Pelin Kıyat, et al.
Published: (2021-06-01)

A pilot study : retinal sensitivity change in neovascular age-related macular degeneration patients with better baseline visual acuity
by: Jae Hyup Lee, et al.
Published: (2024-11-01)

Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept
by: Pallavi Tyagi, et al.
Published: (2018-06-01)

Co-inhibition of PGF and VEGF blocks their expression in mononuclear phagocytes and limits neovascularization and leakage in the murine retina
by: Carsten Balser, et al.
Published: (2019-02-01)

Efficacy and Safety of Biosimilar QL1207 vs. the Reference Aflibercept for Patients with Neovascular Age-Related Macular Degeneration: A Randomized Phase 3 Trial
by: Bing Li, et al.
Published: (2023-11-01)

12-month outcomes of ziv-aflibercept for neovascular age-related macular degeneration in eyes previously treated with aflibercept
by: Wajiha J Kheir, et al.
Published: (2025-01-01)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
by: Alaa Din Abdin, et al.
Published: (2021-12-01)

Choroidal structural changes determined by the binarization method after intravitreal aflibercept treatment in neovascular age-related macular degeneration
by: Emine Temel, et al.
Published: (2021-08-01)

Refractory Age-Related Macular Degeneration Due to Concurrent Central Serous Chorioretinopathy in Previously Well-Controlled Eyes
by: Chikako Hara, et al.
Published: (2023-01-01)

Pro re nata versus fixed aflibercept regimen for neovascular age-related macular degeneration: a systematic review and meta-analysis
by: Andi Arus Victor, et al.
Published: (2022-09-01)

Correlations between subfoveal choroidal thickness, macular thickness, and visual outcome in neovascular age-related macular degeneration using swept source OCT: insights from intravitreal aflibercept treatment
by: Daniel P. Beraldo, et al.
Published: (2023-11-01)

Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial
by: Praveen J. Patel, et al.
Published: (2020-06-01)

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
by: Jean-François Korobelnik, et al.
Published: (2024-01-01)

Efficacy and safety of brolucizumab versus aflibercept in patients with neovascular age-related macular degeneration: a randomized trial in Indian patients
by: Sanjay Kumar Mishra, et al.
Published: (2022-07-01)

Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration
by: Hao Xie, et al.
Published: (2024-05-01)

Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
by: Michel Weber, et al.
Published: (2020-05-01)

COMPARISON OF CLINICAL AND REAL-LIFE TRiaLS OF THE EFFECTIVENESS OF ANTI-VEGF THERAPY FOR age-related macular degeneration
by: M. V. Budzinskaya, et al.
Published: (2019-02-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01)

Aflibercept: a review of its use in the treatment of choroidal neovascularization due to age-related macular degeneration
by: Balaratnasingam C, et al.
Published: (2015-12-01)

Comparison of two different treatment regimens’ efficacy in neovascular age-related macular degeneration in Turkish population—based on real life data-Bosphorus RWE Study Group
by: Burak Erden, et al.
Published: (2020-01-01)

Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
by: Kaiser SM, et al.
Published: (2021-09-01)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
by: Nixon DR, et al.
Published: (2017-04-01)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
by: Henrik Faatz, et al.
Published: (2022-11-01)

Treatment Interval Progression and Adherence to Observe-and-Plan Regimen for Neovascular Age-Related Macular Degeneration Treated with Aflibercept 2 mg
by: Leyla Turan, et al.
Published: (2025-02-01)

Deep Learning in Neovascular Age-Related Macular Degeneration
by: Enrico Borrelli, et al.
Published: (2024-06-01)

Cytokine and Chemokine Profile Changes in Patients with Neovascular Age-Related Macular Degeneration After Intravitreal Ranibizumab Injection for Choroidal Neovascularization
by: Sun T, et al.
Published: (2021-06-01)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
by: Yingbin Fu, et al.
Published: (2024-02-01)

Double-dose investigation of aflibercept in neovascular age-related macular degeneration (DIANA): a real-world study
by: Min Zhang, et al.
Published: (2024-05-01)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
by: Khanani AM, et al.
Published: (2019-02-01)

Emerging therapeutic strategies for unmet need in neovascular age-related macular degeneration
by: Levon M. Khachigian, et al.
Published: (2023-02-01)

Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration
by: Simon D Archambault, et al.
Published: (2024-01-01)

Real-World Outcomes of Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration: A Large-Scale Postmarketing Surveillance in Korea
by: Ryu G, et al.
Published: (2021-08-01)

Removal of choroidal neovascular membrane in a case of macular hole after anti-VEGF therapy for age-related macular degeneration
by: Akira Hirata, et al.
Published: (2018-03-01)

Lamellar macular hole formation following intravitreal bevacizumab injection for choroidal neovascularization by age-related macular degeneration
by: Hamidreza Torabi, et al.
Published: (2018-01-01)

Outcomes and predictive factors for fluid resolution following three loading injections of faricimab for treatment-naïve neovascular age-related macular degeneration
by: Hee Yong Han, et al.
Published: (2025-01-01)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01)